South Asian Journal of Engineering and Technology Research Article

Open Access Full Text Article 152(2025) 57-67 DOI: 10.26524/sajet.2025.15.7

Synthetic Biology Approaches in Reversing Resistance Phenotypes

Shaistha Hayath*

Department of Microbiology, JSS AHER, Bannimantap, Mysore

Corresponding author.
Correspondence: Shaistha Hayath
E-mail: **shaisthahayath16@gmail.com**

Article info
Received 20th November 2024
Revised form 10th January 2025
Accepted 21th February 2025

Keywords
Client experience/fulfilment, CCRF, cost, planning

https://sajet.in/index.php/journal/article/view/311

Abstract
Antimicrobial resistance (AMR) is a growing global health crisis, posing a serious threat to the treatment of bacterial infections. The overuse and misuse of antibiotics have led to the emergence of drug-resistant bacteria, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains. Traditional antibiotic development has failed to keep up with the rapid rise of resistance, necessitating alternative strategies. Synthetic biology, an interdisciplinary field that combines biology with engineering principles, offers promising solutions for reversing bacterial resistance phenotypes. This paper explores how synthetic biology approaches, such as gene editing, engineered antimicrobial peptides, and synthetic bacteriophages, can be utilized to target and disrupt the molecular mechanisms underlying resistance. These strategies have the potential to restore bacterial susceptibility to existing antibiotics, offering more precise and sustainable treatment options compared to conventional drugs. Additionally, the paper addresses the challenges associated with synthetic biology applications, including safety concerns, ethical implications, and the risk of resistance to engineered therapies. Despite these challenges, synthetic biology holds significant promise as a complementary tool in the fight against AMR. The paper highlights the potential of synthetic biology to revolutionize AMR treatment, providing a tailored and innovative approach to combat one of the most urgent public health threats of our time.

INTRODUCTION

Antimicrobial resistance (AMR) has emerged as one of the most significant and urgent public health challenges globally. AMR refers to the ability of microbes, such as bacteria, fungi, viruses, and parasites, to resist the effects of drugs that once killed them or inhibited their growth [1]. This resistance is primarily driven by the overuse and misuse of antibiotics and other antimicrobial agents in human medicine, agriculture, and animal husbandry [2]. As a result, infections caused by resistant pathogens have become increasingly difficult to treat, leading to longer hospital stays, more intensive care, higher healthcare costs, and an increase in morbidity and mortality rates [3].

The development of resistance phenotypes by bacteria, in particular, has gained significant attention due to its impact on treatment efficacy and the rising prevalence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria [3][4]. These resistant strains have rendered many first-line

and second-line antibiotics ineffective, making it challenging for healthcare professionals to manage common infections, let alone complex or life-threatening diseases [3]. This situation has contributed to a global crisis, with the World Health Organization (WHO) predicting that AMR could cause 10 million deaths annually by 2050 if the trend is not reversed [5].

Traditional methods of addressing AMR, such as the development of new antibiotics, have not kept pace with the rapid emergence of resistance. This has led to a growing interest in alternative approaches, such as the application of synthetic biology, to combat bacterial resistance [6][7]. Synthetic biology is a field that combines biological sciences with engineering principles to design and construct new biological systems or modify existing ones for specific functions. This innovative discipline has the potential to transform the way we approach the problem of AMR by providing more precise, effective, and sustainable solutions [6].

In the context of AMR, synthetic biology offers a unique advantage: it enables the development of targeted, custom-designed therapies that can specifically reverse resistance phenotypes in bacteria [8]. By leveraging cutting-edge technologies such as gene editing (e.g., CRISPR-Cas9), synthetic antimicrobial peptides, and engineered bacteria or bacteriophages, synthetic biology can provide new strategies to overcome existing resistance mechanisms [9]. These approaches focus on manipulating genetic material to either disrupt resistance pathways or restore bacterial susceptibility to antibiotics, offering a more tailored and potentially more effective method of treatment compared to conventional antibiotics [10].

This paper explores the potential of synthetic biology in reversing bacterial resistance phenotypes and how it can complement traditional approaches to AMR. The following sections will review the mechanisms of resistance, examine key synthetic biology strategies, and discuss the challenges and ethical considerations associated with the application of synthetic biology in overcoming AMR. By the end of this paper, we aim to present a comprehensive understanding of how synthetic biology could contribute to solving one of the most pressing global health issues of our time.

2. UNDERSTANDING RESISTANCE PHENOTYPES

Resistance phenotypes occur when bacteria acquire or develop the ability to survive exposure to antibiotics that would normally kill them [11]. This resistance arises through genetic mutations or the acquisition of resistance genes from other bacteria via horizontal gene transfer. One of the primary mechanisms of resistance is the production of enzymes like beta-lactamases, which degrade antibiotics such as penicillin [12]. Other common resistance mechanisms include altered antibiotic target sites, efflux pumps that expel the drug from the bacterial cell, and biofilm formation that protects bacteria from the effects of antibiotics [13]. Resistance can be adaptive, occurring rapidly in response to environmental pressures, or acquired, resulting from the transfer of resistance genes between bacteria.

Overuse and misuse of antibiotics in clinical settings, agriculture, and animal husbandry contribute significantly to the spread of resistance [14]. The development of resistance phenotypes poses a major threat to public health, as it leads to infections that are difficult to treat and may result in prolonged illness, higher mortality, and increased healthcare costs. Understanding these mechanisms is critical for developing new strategies to combat resistance, such as synthetic biology-based approaches that can directly target and disrupt these resistance pathways [15].

3. SYNTHETIC BIOLOGY: A TOOL FOR COMBATTING AMR

Synthetic biology is an interdisciplinary field that combines biology, engineering, and computer science to design and construct new biological parts, devices, and systems with novel functionalities. This approach allows for the creation of microorganisms and molecular systems that do not exist in nature but can be programmed to perform specific tasks [16]. One of the key principles of synthetic biology is the ability to manipulate genetic material to design systems with desired behaviors. This includes gene synthesis, CRISPR-Cas9 gene editing, and the creation of synthetic circuits that can regulate gene expression in response to environmental cues. In the context of AMR, synthetic biology holds great promise by enabling the development of targeted therapies that can reverse resistance mechanisms [6]. For example, synthetic biology could be used to engineer bacteria that can degrade resistance-conferring genes or to develop antimicrobial peptides that bypass existing resistance mechanisms. Additionally, synthetic circuits can be designed to precisely control the release of therapeutic agents, making treatments more effective while minimizing side effects. Compared to traditional approaches, synthetic biology offers a more flexible and customizable platform for addressing the complex problem of antimicrobial resistance [9].

4. REVERSING RESISTANCE PHENOTYPES THROUGH SYNTHETIC BIOLOGY

One of the most promising applications of synthetic biology in reversing resistance phenotypes is the use of gene editing technologies, particularly CRISPR-Cas9. This tool enables precise modifications to bacterial genomes, allowing scientists to target and deactivate resistance genes or restore susceptibility to antibiotics [17]. By editing bacterial genes involved in resistance, such as those encoding beta-lactamases or efflux pumps, researchers can reduce or eliminate the bacteria's ability to resist treatment. In addition to gene editing, synthetic biology offers the potential for developing synthetic antimicrobial peptides (AMPs), which can disrupt bacterial membranes and bypass resistance mechanisms such as beta-lactamase production [9]. These peptides, which are engineered to target specific bacterial strains, offer a highly targeted alternative to broad-spectrum antibiotics. Another approach is the reprogramming of bacterial metabolic pathways to restore susceptibility to antibiotics [18]. For instance, synthetic biology can be used to engineer bacteria that can metabolize resistance-conferring elements or produce molecules that block resistance mechanisms [3]. Additionally, the development of

engineered bacteriophages—viruses that specifically target bacteria—can be employed to target resistant bacterial strains and reverse their resistance phenotypes [19]. These synthetic biology strategies offer the potential to restore the effectiveness of existing antibiotics, offering a more sustainable solution to AMR.

5. SYNTHETIC BIOLOGY APPLICATIONS IN OVERCOMING MULTI-DRUG RESISTANCE

Multi-drug resistance (MDR) is a significant challenge in treating bacterial infections, where bacteria develop resistance to multiple classes of antibiotics, often through the overproduction of efflux pumps that expel antibiotics from the bacterial cell [20]. Synthetic biology approaches have the potential to target and inhibit the function of these MDR efflux pumps, which are responsible for the rapid expulsion of drugs from bacterial cells. One strategy is to engineer synthetic molecules or peptides that can block the activity of efflux pumps, thereby restoring the potency of antibiotics [21]. Another promising approach is the creation of dual-functionality systems, which combine antimicrobial agents with efflux pump inhibitors in a single therapeutic package [22]. These systems could not only target the bacteria directly but also reduce their ability to expel the antibiotics, making them more effective. Additionally, synthetic biology can be used to engineer bacteria that carry resistance-reversing genes or molecular systems, which can be delivered to infected sites to break down the resistance mechanisms [6]. These engineered bacteria could potentially act as living therapeutics, providing a novel way to overcome multi-drug resistance. The integration of synthetic biology with existing antibiotic therapies could lead to more effective treatments, even for infections caused by multi-drug-resistant bacteria [9].

6. CHALLENGES AND ETHICAL CONSIDERATIONS

While synthetic biology holds great promise in reversing resistance phenotypes and combating AMR, there are several challenges that must be addressed. One major concern is the safety of genetically modified organisms (GMOs), especially when they are released into the environment or used in clinical settings [6]. The unintended consequences of introducing engineered bacteria or other organisms into the human microbiome or ecosystems need careful evaluation to avoid disrupting natural microbial communities or causing harm. Another challenge is the development of resistance to synthetic biology-based treatments, particularly in the case of engineered bacteriophages or antimicrobial peptides. Bacteria may evolve resistance mechanisms against these novel treatments, necessitating continuous monitoring and adaptation [6]. Additionally, there are significant ethical and regulatory concerns surrounding the use of genetic modification in medical applications. Questions around the long-term effects of genetic modifications, the potential for misuse, and the regulation of synthetic biology-based therapies need to be addressed to ensure the responsible use of these technologies. Public perception is also a critical issue, as people may have concerns about the safety and efficacy of genetically engineered treatments [23]. Overcoming these challenges requires interdisciplinary collaboration, careful

regulation, and public engagement to ensure the successful and ethical application of synthetic biology in the fight against AMR.

7. FUTURE DIRECTIONS AND RESEARCH NEEDS

The future of synthetic biology in reversing resistance phenotypes and combating AMR is promising, but further research is necessary to optimize and expand its applications. One of the most exciting developments is the potential for synthetic biology to integrate with other therapeutic approaches, such as vaccines, probiotics, and traditional antibiotics [24]. For example, engineered bacteria could be used to deliver vaccines or other therapeutic agents directly to infected tissues, enhancing treatment efficacy. Moreover, advances in genetic engineering and gene editing techniques, such as CRISPR-based systems and synthetic gene circuits, will continue to improve the precision and scalability of synthetic biology applications [25]. As the field of synthetic biology matures, there will likely be increased focus on the creation of personalized treatments, where therapies are tailored to the genetic profile of specific bacterial infections. This could lead to more effective treatments with fewer side effects. Collaborative efforts between academic researchers, healthcare providers, industry, and regulatory agencies will be critical in advancing synthetic biology as a mainstream solution to AMR [3]. By fostering innovation, addressing regulatory hurdles, and ensuring safety and effectiveness, synthetic biology could become a cornerstone of future strategies to combat drug-resistant infections [15].

8. CONCLUSION

In conclusion, synthetic biology represents a transformative approach in the battle against antimicrobial resistance (AMR), offering innovative solutions that could significantly improve our ability to treat drug-resistant infections. As AMR continues to escalate, the traditional methods of developing new antibiotics are increasingly inadequate. This highlights the urgent need for alternative therapeutic strategies. Synthetic biology, with its potential for designing and constructing tailored biological systems, presents a unique opportunity to reverse bacterial resistance phenotypes. By employing cutting-edge technologies such as gene editing (e.g., CRISPR-Cas9), synthetic antimicrobial peptides, engineered bacteria, and bacteriophages, synthetic biology has the capacity to directly target and manipulate bacterial resistance mechanisms, restoring the efficacy of existing antibiotics or even providing entirely new therapeutic avenues.

These strategies not only hold promise for overcoming resistance in commonly encountered pathogens but also offer potential solutions for tackling multi-drug-resistant (MDR) and extensively drug-resistant (XDR) bacteria, which are increasingly common in clinical settings. However, the successful integration of synthetic biology into clinical practice is not without challenges. Safety concerns regarding genetically modified organisms (GMOs), the risk of engineered bacteria evolving resistance,

and ethical dilemmas related to the modification of living organisms all require careful consideration and regulation.

Despite these challenges, the future of synthetic biology in the fight against AMR is highly promising. Continued research, technological advancements, and interdisciplinary collaboration are crucial for refining these strategies and ensuring their safety and efficacy. As synthetic biology techniques advance, they could offer a sustainable, long-term solution to the global AMR crisis. In essence, the integration of synthetic biology into AMR treatment paradigms has the potential to revolutionize our approach to infectious disease management, contributing to improved health outcomes and a reduction in the devastating impacts of antibiotic-resistant infections.

Acknowledgement

Nill

Funding

No funding was received to carry out this study.

REFERENCES

1. OLIVEIRA, M., ANTUNES, W., MOTA, S., MADUREIRA-CARVALHO, Á., DINIS-OLIVEIRA, R. J., & SILVA, D. D. DA. (2024). AN OVERVIEW OF THE RECENT ADVANCES IN ANTIMICROBIAL RESISTANCE [REVIEW OF AN OVERVIEW OF THE RECENT ADVANCES IN ANTIMICROBIAL RESISTANCE]. MICROORGANISMS, 12(9), 1920. MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE. HTTPS://DOI.ORG/10.3390/MICROORGANISMS12091920
2. BAKER, S., NIRANJAN, RAJ. S., MANJU, K., RANJINI, H. K., & SHAYISTA, H. (2023). EFFICACY OF BREAST MILK COMPONENTS AGAINST MICROBIAL PATHOGENS TO COMBAT DRUG-RESISTANCE. THE MICROBE, 1, 100010. HTTPS://DOI.ORG/10.1016/J.MICROB.2023.100010
3. NIÑO-VEGA, G. A., ORTIZ-RAMÍREZ, J. A., & LÓPEZ-ROMERO, E. (2025). NOVEL ANTIBACTERIAL APPROACHES AND THERAPEUTIC STRATEGIES. ANTIBIOTICS, 14(4), 404. HTTPS://DOI.ORG/10.3390/ANTIBIOTICS14040404
4. NIÑO-VEGA, G. A., ORTIZ-RAMÍREZ, J. A., & LÓPEZ-ROMERO, E. (2025). NOVEL ANTIBACTERIAL APPROACHES AND THERAPEUTIC STRATEGIES. ANTIBIOTICS, 14(4), 404. HTTPS://DOI.ORG/10.3390/ANTIBIOTICS14040404
5. BAKER, S., PERIANOVA, O. V., PRUDNIKOVA, S. V., KUZMIN, A., POTKINA, N. K., KHOHLOVA, O. Y., & LOBOVA, T. I. (2020). PHYTOGENIC NANOPARTICLES

TO COMBAT MULTI DRUG RESISTANT PATHOGENS AND PHOTOCATALYTIC DEGRADATION OF DYES. BIONANOSCIENCE, 10(2), 486-492.

6. NIÑO-VEGA, G. A., ORTIZ-RAMÍREZ, J. A., & LÓPEZ-ROMERO, E. (2025). NOVEL ANTIBACTERIAL APPROACHES AND THERAPEUTIC STRATEGIES. ANTIBIOTICS, 14(4), 404. HTTPS://DOI.ORG/10.3390/ANTIBIOTICS14040404
7. ESTANY-GESTAL, A., SALGADO-BARREIRA, Á., & LAGO, J. M. V. (2024). ANTIBIOTIC USE AND ANTIMICROBIAL RESISTANCE: A GLOBAL PUBLIC HEALTH CRISIS. ANTIBIOTICS, 13(9), 900. HTTPS://DOI.ORG/10.3390/ANTIBIOTICS13090900
8. COOK, G. D., & STASULLI, N. M. (2024). EMPLOYING SYNTHETIC BIOLOGY TO EXPAND ANTIBIOTIC DISCOVERY. SLAS TECHNOLOGY, 29(2), 100120. HTTPS://DOI.ORG/10.1016/J.SLAST.2024.100120
9. SYED, B., PRUDNIKOVA, S. V., PERIANOVA, O. V., ZHARKOV, S. M., KUZMIN, A., CHOUHAN, R. S., ... & SINGH, M. (2019). PHYTOGENIC SYNTHESIS OF AG BIONANO-ANTIBIOTICS AGAINST ESKAPE DRUG RESISTANT COMMUNITIES IN KRASNOYARSK, SIBERIA. JOURNAL OF CLUSTER SCIENCE, 30, 589-597.
10. COOK, G. D., & STASULLI, N. M. (2024). EMPLOYING SYNTHETIC BIOLOGY TO EXPAND ANTIBIOTIC DISCOVERY. SLAS TECHNOLOGY, 29(2), 100120. HTTPS://DOI.ORG/10.1016/J.SLAST.2024.100120
11. AHMED, S. K., HUSSEIN, S., QURBANI, K., IBRAHIM, R. H., FAREEQ, A., MAHMOOD, K. A., & MOHAMED, M. G. (2024). ANTIMICROBIAL RESISTANCE: IMPACTS, CHALLENGES, AND FUTURE PROSPECTS. JOURNAL OF MEDICINE SURGERY AND PUBLIC HEALTH, 2, 100081. HTTPS://DOI.ORG/10.1016/J.GLMEDI.2024.100081
12. ARI, M. M., DADGAR, L., ELAHI, Z. Y., GHANAVATI, R., & TAHERI, B. (2024). GENETICALLY ENGINEERED MICROORGANISMS AND THEIR IMPACT ON HUMAN HEALTH [REVIEW OF GENETICALLY ENGINEERED MICROORGANISMS AND THEIR IMPACT ON HUMAN HEALTH]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2024, 1. WILEY. HTTPS://DOI.ORG/10.1155/2024/6638269
13. CHAVADA, J., MUNESHWAR, K. N., GHULAXE, Y., WANI, M., SARDA, P. P., & HUSE, S. (2023). ANTIBIOTIC RESISTANCE: CHALLENGES AND STRATEGIES IN COMBATING INFECTIONS. CUREUS. CUREUS, INC. HTTPS://DOI.ORG/10.7759/CUREUS.46013

14. BAKER, S., & PERIANOVA, O. V. (2019). BIO-NANOBACTERICIDES: AN EMANATING CLASS OF NANOPARTICLES TOWARDS COMBATING MULTI-DRUG RESISTANT PATHOGENS. SN APPLIED SCIENCES, 1(7), 699.
15. HITCHCOCK, N., NUNES, D. D. G., SHIACH, J., HODEL, K. V. S., BARBOSA, J. D. V., RODRIGUES, L. A. P., COLER, B., SOARES, M. B. P., & BADARÓ, R. (2023). CURRENT CLINICAL LANDSCAPE AND GLOBAL POTENTIAL OF BACTERIOPHAGE THERAPY. VIRUSES, 15(4), 1020. MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE. HTTPS://DOI.ORG/10.3390/V15041020
16. SYED, B., PRASAD, M. N., KUMAR, K. M., & SATISH, S. (2018). BIOCONJUGATED NANO-BACTERICIDAL COMPLEX FOR POTENT ACTIVITY AGAINST HUMAN AND PHYTOPATHOGENS WITH CONCERN OF GLOBAL DRUG RESISTANT CRISIS. SCIENCE OF THE TOTAL ENVIRONMENT, 637, 274-281.
17. GALGANO, M., PELLEGRINI, F., CATALANO, E., CAPOZZI, L., SAMBRO, L. D., SPOSATO, A., LUCENTE, M. S., VASINIOTI, V. I., CATELLA, C., ODIGIE, A. E., TEMPESTA, M., PRATELLI, A., & CAPOZZA, P. (2025). ACQUIRED BACTERIAL RESISTANCE TO ANTIBIOTICS AND RESISTANCE GENES: FROM PAST TO FUTURE. ANTIBIOTICS, 14(3), 222. MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE. HTTPS://DOI.ORG/10.3390/ANTIBIOTICS14030222
18. ELSHOBARY, M. E., BADAWY, N. K., KAMEL, Y. A., ZATIOUN, A. A., MASRIYA, H. H., AMMAR, M., MOHAMED, N. A., MOURAD, S., & ASSY, A. M. (2025). COMBATING ANTIBIOTIC RESISTANCE: MECHANISMS, MULTIDRUG-RESISTANT PATHOGENS, AND NOVEL THERAPEUTIC APPROACHES: AN UPDATED REVIEW. PHARMACEUTICALS, 18(3), 402. MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE. HTTPS://DOI.ORG/10.3390/PH18030402
19. KARIM, A. S., BROWN, D. M., ARCHULETA, C. M., GRANNAN, S., ARISTILDE, L., GOYAL, Y., LEONARD, J. N., MANGAN, N. M., PRINDLE, A., ROCKLIN, G. J., TYO, K. E. J., ZOLOTH, L., JEWETT, M. C., CALKINS, S., KAMAT, N. P., TULLMAN-ERCEK, D., & LUCKS, J. B. (2024). DECONSTRUCTING SYNTHETIC BIOLOGY ACROSS SCALES: A CONCEPTUAL APPROACH FOR TRAINING SYNTHETIC BIOLOGISTS. NATURE COMMUNICATIONS, 15(1). HTTPS://DOI.ORG/10.1038/S41467-024-49626-X
20. COOK, G. D., & STASULLI, N. M. (2024). EMPLOYING SYNTHETIC BIOLOGY TO EXPAND ANTIBIOTIC DISCOVERY. SLAS TECHNOLOGY, 29(2), 100120. HTTPS://DOI.ORG/10.1016/J.SLAST.2024.100120

21. ARI, M. M., DADGAR, L., ELAHI, Z. Y., GHANAVATI, R., & TAHERI, B. (2024). GENETICALLY ENGINEERED MICROORGANISMS AND THEIR IMPACT ON HUMAN HEALTH [REVIEW OF GENETICALLY ENGINEERED MICROORGANISMS AND THEIR IMPACT ON HUMAN HEALTH]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2024, 1. WILEY. HTTPS://DOI.ORG/10.1155/2024/6638269
22. ARI, M. M., DADGAR, L., ELAHI, Z. Y., GHANAVATI, R., & TAHERI, B. (2024). GENETICALLY ENGINEERED MICROORGANISMS AND THEIR IMPACT ON HUMAN HEALTH [REVIEW OF GENETICALLY ENGINEERED MICROORGANISMS AND THEIR IMPACT ON HUMAN HEALTH]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2024, 1. WILEY. HTTPS://DOI.ORG/10.1155/2024/6638269
23. ARI, M. M., DADGAR, L., ELAHI, Z. Y., GHANAVATI, R., & TAHERI, B. (2024). GENETICALLY ENGINEERED MICROORGANISMS AND THEIR IMPACT ON HUMAN HEALTH [REVIEW OF GENETICALLY ENGINEERED MICROORGANISMS AND THEIR IMPACT ON HUMAN HEALTH]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2024, 1. WILEY. HTTPS://DOI.ORG/10.1155/2024/6638269
24. XUAN, J., FENG, W., WANG, J., WANG, R., ZHANG, B., BO, L., CHEN, Z., YANG, H., & SUN, L. (2023). ANTIMICROBIAL PEPTIDES FOR COMBATING DRUG-RESISTANT BACTERIAL INFECTIONS . DRUG RESISTANCE UPDATES, 68, 100954. ELSEVIER BV. HTTPS://DOI.ORG/10.1016/J.DRUP.2023.100954
25. NIÑO-VEGA, G. A., ORTIZ-RAMÍREZ, J. A., & LÓPEZ-ROMERO, E. (2025). NOVEL ANTIBACTERIAL APPROACHES AND THERAPEUTIC STRATEGIES. ANTIBIOTICS, 14(4), 404. HTTPS://DOI.ORG/10.3390/ANTIBIOTICS14040404
26. SZYMCZAK, M., PANKOWSKI, J. A., KWIATEK, A., GRYGORCEWICZ, B., KARCZEWSKA-GOLEC, J., SADOWSKA, K., & GOLEC, P. (2024). AN EFFECTIVE ANTIBIOFILM STRATEGY BASED ON BACTERIOPHAGES ARMED WITH SILVER NANOPARTICLES. SCIENTIFIC REPORTS, 14(1). HTTPS://DOI.ORG/10.1038/S41598-024-59866-Y
27. SHAYISTA, H., PRASAD, M. N. N., RAJ, S. N., PRASAD, A., SATISH, S., RANJINI, H. K., MANJU, K., RAVIKUMARA, CHOUHAN, R. S., KHOHLOVA, O. Y., ПЕРЬЯНОВА, O. B., LAKSHMI, S., & BAKER, S. (2025). IMPACT OF MACROLIDE ANTIBIOTICS ON GUT MICROBIOTA DIVERSITY WITH AGE-SPECIFIC

IMPLICATIONS AND SCIENTIFIC INSIGHTS. MEDICINE IN MICROECOLOGY, 100122. HTTPS://DOI.ORG/10.1016/J.MEDMIC.2025.100122

28. ZHANG, L., TIAN, X., SUN, L., MI, K., WANG, R., GONG, F., & HUANG, L. (2024). BACTERIAL EFFLUX PUMP INHIBITORS REDUCE ANTIBIOTIC RESISTANCE. PHARMACEUTICS, 16(2), 170. HTTPS://DOI.ORG/10.3390/PHARMACEUTICS16020170
29. SILVA, L. Y. S. DA, PAULO, C. L. R., MOURA, T. F., ALVES, D. S., PESSOA, R. T., ARAÚJO, I. M., OLIVEIRA-TINTINO, C. D. DE M., TINTINO, S. R., NONATO, C. DE F. A., COSTA, J. G. M. DA, RIBEIRO-FILHO, J., COUTINHO, H. D. M., KOWALSKA, G., MITURA, P., BAR, M., KOWALSKI, R., & MENEZES, I. R. A. DE. (2023). ANTIBACTERIAL ACTIVITY OF THE ESSENTIAL OIL OF PIPER TUBERCULATUM JACQ. FRUITS AGAINST MULTIDRUG-RESISTANT STRAINS: INHIBITION OF EFFLUX PUMPS AND B-LACTAMASE. PLANTS, 12(12), 2377. HTTPS://DOI.ORG/10.3390/PLANTS12122377
30. COOK, G. D., & STASULLI, N. M. (2024). EMPLOYING SYNTHETIC BIOLOGY TO EXPAND ANTIBIOTIC DISCOVERY. SLAS TECHNOLOGY, 29(2), 100120. HTTPS://DOI.ORG/10.1016/J.SLAST.2024.100120
31. ARI, M. M., DADGAR, L., ELAHI, Z. Y., GHANAVATI, R., & TAHERI, B. (2024). GENETICALLY ENGINEERED MICROORGANISMS AND THEIR IMPACT ON HUMAN HEALTH [REVIEW OF GENETICALLY ENGINEERED MICROORGANISMS AND THEIR IMPACT ON HUMAN HEALTH]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2024, 1. WILEY. HTTPS://DOI.ORG/10.1155/2024/6638269
32. COOK, G. D., & STASULLI, N. M. (2024). EMPLOYING SYNTHETIC BIOLOGY TO EXPAND ANTIBIOTIC DISCOVERY. SLAS TECHNOLOGY, 29(2), 100120. HTTPS://DOI.ORG/10.1016/J.SLAST.2024.100120
33. COOK, G. D., & STASULLI, N. M. (2024). EMPLOYING SYNTHETIC BIOLOGY TO EXPAND ANTIBIOTIC DISCOVERY. SLAS TECHNOLOGY, 29(2), 100120. HTTPS://DOI.ORG/10.1016/J.SLAST.2024.100120
34. BIFULCO, M., ZAZZO, E. D., AFFINITO, A., & PAGANO, C. (2025). THE RELEVANCE OF THE HISTORY OF BIOTECHNOLOGY FOR HEALTHCARE. EMBO REPORTS. HTTPS://DOI.ORG/10.1038/S44319-024-00355-8
35. HABTEWELD, H. A., & ASFAW, T. (2023). NOVEL DIETARY APPROACH WITH PROBIOTICS, PREBIOTICS, AND SYNBIOTICS TO MITIGATE ANTIMICROBIAL

RESISTANCE AND SUBSEQUENT OUT MARKETPLACE OF ANTIMICROBIAL AGENTS: A REVIEW [REVIEW OF NOVEL DIETARY APPROACH WITH PROBIOTICS, PREBIOTICS, AND SYNBIOTICS TO MITIGATE ANTIMICROBIAL RESISTANCE AND SUBSEQUENT OUT MARKETPLACE OF ANTIMICROBIAL AGENTS: A REVIEW]. INFECTION AND DRUG RESISTANCE, 3191. DOVE MEDICAL PRESS. HTTPS://DOI.ORG/10.2147/IDR.S413416

36. XU, W., ZHANG, S., QIN, H., & YAO, K. (2024). FROM BENCH TO BEDSIDE: CUTTING-EDGE APPLICATIONS OF BASE EDITING AND PRIME EDITING IN PRECISION MEDICINE. JOURNAL OF TRANSLATIONAL MEDICINE, 22(1). BIOMED CENTRAL. HTTPS://DOI.ORG/10.1186/S12967-024-05957-3
37. NIÑO-VEGA, G. A., ORTIZ-RAMÍREZ, J. A., & LÓPEZ-ROMERO, E. (2025). NOVEL ANTIBACTERIAL APPROACHES AND THERAPEUTIC STRATEGIES. ANTIBIOTICS, 14(4), 404. HTTPS://DOI.ORG/10.3390/ANTIBIOTICS14040404
38. ELSHOBARY, M. E., BADAWY, N. K., KAMEL, Y. A., ZATIOUN, A. A., MASRIYA, H. H., AMMAR, M., MOHAMED, N. A., MOURAD, S., & ASSY, A. M. (2025). COMBATING ANTIBIOTIC RESISTANCE: MECHANISMS, MULTIDRUG-RESISTANT PATHOGENS, AND NOVEL THERAPEUTIC APPROACHES: AN UPDATED REVIEW. PHARMACEUTICALS, 18(3), 402. MULTIDISCIPLINARY DIGITAL PUBLISHING INSTITUTE. HTTPS://DOI.ORG/10.3390/PH18030402